Structures, targets and recent approaches in anti-leishmanial drug discovery and development

Open Medicinal Chemistry Journal

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 31-39

  Seifert, Karin ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Drug development; Drug discovery; Leishmaniasis

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ALENDRONIC ACID; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFLAGELLATE AGENT; ANTILEISHMANIAL AGENT; BUPARVAQUONE; COPOLYMER; CREATINE KINASE; GLYCOGEN SYNTHASE KINASE 3; MEGLUMINE ANTIMONATE; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; PAROMOMYCIN; PENTAMIDINE; PLACEBO; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; PROTEIN KINASE; QUINOLINOL DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; WR 279396;

ABDOMINAL PAIN; ANTIPROTOZOAL ACTIVITY; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CYANOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE PAIN; KIDNEY DISEASE; LEISHMANIASIS; NONHUMAN; OTOTOXICITY; PARASITEMIA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

EID: 80455174235     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501105010031     Document Type: Review

References (119)

1. Reithinger, R.; Dujardin, J. C.; Louzir, H.; Pirmez, C.; Alexander, B.; Brooker, S. Cutaneous leishmaniasis. Lancet Infect. Dis., 2007, 7, 581-96.
2. Bates, P. A. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int. J. Parasitol., 2007, 37, 1097-106.
3. Rogers, M. E.; Ilg, T.; Nikolaev, A. V.; Ferguson, M. A.; Bates, P. A. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature., 2004, 430, 463-7.
4. Burchmore, R. J.; Barrett, M. P. Life in vacuoles--nutrient acquisition by Leishmania amastigotes. Int. J. Parasitol., 2001, 31, 1311-20.
5. Handman, E.; Bullen, D. V. Interaction of Leishmania with the host macrophage. Trends Parasitol., 2002, 18, 332-4.
6. Feasey, N.; Wansbrough-Jones, M.; Mabey, D. C.; Solomon, A. W. Neglected tropical diseases. Br. Med. Bull., 2010, 93, 179-200.
7. Alvar, J.; Yactayo, S.; Bern, C. Leishmaniasis and poverty. Trends Parasitol., 2006, 22, 552-7.
8. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol., 2007, 5, 873-82.
9. Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev., 2006, 19, 111-26.
10. Sundar, S.; More, D. K.; Singh, M. K.; Singh, V. P.; Sharma, S.; Makharia, A.; Kumar, P. C.; Murray, H. W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis., 2000, 31, 1104-7.
11. Alvar, J.; Croft, S.; Olliaro, P. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol., 2006, 61, 223-74.
12. Olliaro, P. L.; Guerin, P. J.; Gerstl, S.; Haaskjold, A. A.; Rottingen, J. A.; Sundar, S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis., 2005, 5, 763-74.
13. Sundar, S.; Sinha, P. R.; Agrawal, N. K.; Srivastava, R.; Rainey, P. M.; Berman, J. D.; Murray, H. W.; Singh, V. P. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg., 1998, 59, 139-43.
14. Chulay, J. D.; Fleckenstein, L.; Smith, D. H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg., 1988, 82, 69-72.
15. Valladares, J. E.; Riera, C.; Alberola, J.; Gallego, M.; Portus, M.; Cristofol, C.; Franquelo, C.; Arboix, M. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet. Parasitol., 1998, 75, 33-40.
16. Frezard, F.; Martins, P. S.; Barbosa, M. C.; Pimenta, A. M.; Ferreira, W. A.; de Melo, J. E.; Mangrum, J. B.; Demicheli, C. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. J. Inorg. Biochem., 2008, 102, 656-65.
17. Berman, J. D.; Waddell, D.; Hanson, B. D. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents. Chemother., 1985, 27, 916-20.
18. Berman, J. D.; Gallalee, J. V.; Best, J. M. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol., 1987, 36, 197-201.
19. Wyllie, S.; Cunningham, M. L.; Fairlamb, A. H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem., 2004, 279, 39925-32.
20. Meyerhoff, A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis., 1999, 28, 42-8; discussion 49-51.
21. Sundar, S.; Mehta, H.; Suresh, A. V.; Singh, S. P.; Rai, M.; Murray, H. W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis., 2004, 38, 377-83.
22. Sundar, S.; Agrawal, G.; Rai, M.; Makharia, M. K.; Murray, H. W. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ., 2001, 323, 419-22.
23. Sundar, S.; Jha, T. K.; Thakur, C. P.; Mishra, M.; Singh, V. P.; Buffels, R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis., 2003, 37, 800-4.
24. Sundar, S.; Chakravarty, J.; Agarwal, D.; Rai, M.; Murray, H. W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med., 2010, 362, 504-12.
25. Sundar, S.; Mehta, H.; Chhabra, A.; Singh, V.; Chauhan, V.; Desjeux, P.; Rai, M. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis., 2006, 42, 608-13.
26. Sundar, S.; Singh, A.; Agarwal, D.; Rai, M.; Agrawal, N.; Chakravarty, J. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg., 2009, 80, 700-3.
27. Sundar, S.; Chakravarty, J.; Agarwal, D.; Shah, A.; Agrawal, N.; Rai, M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop. Med. Int. Health., 2008, 13, 1208-12.
28. Olliaro, P.; Darley, S.; Laxminarayan, R.; Sundar, S. Costeffectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health., 2009, 14, 918-25.
29. Bern, C.; Adler-Moore, J.; Berenguer, J.; Boelaert, M.; den Boer, M.; Davidson, R. N.; Figueras, C.; Gradoni, L.; Kafetzis, D. A.; Ritmeijer, K.; Rosenthal, E.; Royce, C.; Russo, R.; Sundar, S.; Alvar, J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis., 2006, 43, 917-24.
30. Adler-Moore, J.; Proffitt, R. T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother., 2002, 49 (Suppl 1), 21-30.
31. WHO, Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis. WHO/CDS/NTD/IDM/2007.4 2007.
32. Gradoni, L.; Davidson, R. N.; Orsini, S.; Betto, P.; Giambenedetti, M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J. Drug Target., 1993, 1, 311-6.
33. Pourshafie, M.; Morand, S.; Virion, A.; Rakotomanga, M.; Dupuy, C.; Loiseau, P. M. Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin BResistant promastigotes. Antimicrob. Agents Chemother., 2004, 48, 2409-14.
34. Brajtburg, J.; Bolard, J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev., 1996, 9, 512-31.
35. Sindermann, H.; Engel, J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2006, 100 Suppl 1, S17-20.
36. Bhattacharya, S. K.; Sinha, P. K.; Sundar, S.; Thakur, C. P.; Jha, T. K.; Pandey, K.; Das, V. R.; Kumar, N.; Lal, C.; Verma, N.; Singh, V. P.; Ranjan, A.; Verma, R. B.; Anders, G.; Sindermann, H.; Ganguly, N. K. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis., 2007, 196, 591-8.
37. Dorlo, T. P.; van Thiel, P. P.; Huitema, A. D.; Keizer, R. J.; de Vries, H. J.; Beijnen, J. H.; de Vries, P. J. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents. Chemother., 2008, 52, 2855-60.
38. Bryceson, A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health., 2001, 6, 928-34.
39. Seifert, K.; Matu, S.; Javier Perez-Victoria, F.; Castanys, S.; Gamarro, F.; Croft, S. L. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents., 2003, 22, 380-7.
40. Seifert, K.; Perez-Victoria, F. J.; Stettler, M.; Sanchez-Canete, M. P.; Castanys, S.; Gamarro, F.; Croft, S. L. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents, 2007, 30, 229-35.
41. Perez-Victoria, F. J.; Gamarro, F.; Ouellette, M.; Castanys, S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem., 2003, 278, 49965-71.
42. Perez-Victoria, F. J.; Sanchez-Canete, M. P.; Castanys, S.; Gamarro, F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem., 2006, 281, 23766-75.
43. Perez-Victoria, F. J.; Sanchez-Canete, M. P.; Seifert, K.; Croft, S. L.; Sundar, S.; Castanys, S.; Gamarro, F. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug. Resist. Updat., 2006, 9, 26-39.
44. Lux, H.; Hart, D. T.; Parker, P. J.; Klenner, T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol., 1996, 416, 201-211.
45. Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Opperdoes, F. R. Ether-- lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania. Mol. Biochem. Parasitol., 2000, 111, 1-14.
46. Luque-Ortega, J. R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51, 1327-32.
47. Rakotomanga, M.; Blanc, S.; Gaudin, K.; Chaminade, P.; Loiseau, P. M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51, 1425-30.
48. Sundar, S.; Jha, T. K.; Thakur, C. P.; Sinha, P. K.; Bhattacharya, S. K. Injectable paromomycin for Visceral leishmaniasis in India. N. Engl. J. Med., 2007, 356, 2571-81.
49. Sundar, S.; Agrawal, N.; Arora, R.; Agarwal, D.; Rai, M.; Chakravarty, J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin. Infect. Dis., 2009, 49, 914-8.
50. Davidson, R. N.; den Boer, M.; Ritmeijer, K. Paromomycin. Trans. R. Soc. Trop. Med. Hyg., 2009, 103, 653-60.
51. Ben Salah, A.; Buffet, P. A.; Morizot, G.; Ben Massoud, N.; Zaatour, A.; Ben Alaya, N.; Haj Hamida, N. B.; El Ahmadi, Z.; Downs, M. T.; Smith, P. L.; Dellagi, K.; Grogl, M. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl. Trop. Dis., 2009, 3, e432.
52. Garnier, T.; Croft, S. L. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs, 2002, 3, 538-44.
53. Kanyok, T. P.; Killian, A. D.; Rodvold, K. A.; Danziger, L. H. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob. Agents. Chemother., 1997, 41, 982-6.
54. Maarouf, M.; Lawrence, F.; Croft, S. L.; Robert-Gero, M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res., 1995, 81, 421-5.
55. Maarouf, M.; de Kouchkovsky, Y.; Brown, S.; Petit, P. X.; Robert-Gero, M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell. Res., 1997, 232, 339-48.
56. Maarouf, M.; Lawrence, F.; Brown, S.; Robert-Gero, M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res., 1997, 83, 198-202.
57. Maarouf, M.; Adeline, M. T.; Solignac, M.; Vautrin, D.; Robert-Gero, M. Development and characterization of paromomycinresistant Leishmania donovani promastigotes. Parasite., 1998, 5, 167-73.
58. Jhingran, A.; Chawla, B.; Saxena, S.; Barrett, M. P.; Madhubala, R. Paromomycin: uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 2009, 164, 111-7.
59. Langreth, S. G.; Berman, J. D.; Riordan, G. P.; Lee, L. S. Finestructural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J. Protozool., 1983, 30, 555-61.
60. Croft, S. L.; Brazil, R. P. Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann. Trop. Med. Parasitol., 1982, 76, 37-43.
61. +, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem. J., 1992, 284, 463-7.
62. Vercesi, A. E.; Rodrigues, C. O.; Catisti, R.; Docampo, R. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Lett., 2000, 473, 203-6.
63. Mukherjee, A.; Padmanabhan, P. K.; Sahani, M. H.; Barrett, M. P.; Madhubala, R. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 2006, 145, 1-10.
64. Basselin, M.; Denise, H.; Coombs, G. H.; Barrett, M. P. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents. Chemother., 2002, 46, 3731-8.
65. Yeates, C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs., 2002, 3, 1446-52.
66. Tekwani, B. L.; Walker, L. A. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis., 2006, 19, 623-31.
67. Wasunna, M. K.; Rashid, J. R.; Mbui, J.; Kirigi, G.; Kinoti, D.; Lodenyo, H.; Felton, J. M.; Sabin, A. J.; Albert, M. J.; Horton, J. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg., 2005, 73, 871-6.
68. Jha, T. K.; Sundar, S.; Thakur, C. P.; Felton, J. M.; Sabin, A. J.; Horton, J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg., 2005, 73, 1005-11.
69. Theoharides, A. D.; Chung, H.; Velazquez, H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochem. Pharmacol., 1985, 34, 181-8.
70. Idowu, O. R.; Peggins, J. O.; Brewer, T. G. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents. Drug. Metab. Dispos., 1995, 23, 18-27.
71. Taylor, T.; Hawkins, D. R.; Morris, G. R.; Chung, H. Pharmacokinetics of the anti-leishmanian agent WR 6026 in dogs. Eur. J. Drug. Metab. Pharmacokinet., 1991, Spec No 3, 136-9.
72. Lopez-Martin, C.; Perez-Victoria, J. M.; Carvalho, L.; Castanys, S.; Gamarro, F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob. Agents Chemother., 2008, 52, 4030-6.
73. Duenas-Romero, A. M.; Loiseau, P. M.; Saint-Pierre-Chazalet, M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochim. Biophys. Acta., 2007, 1768, 246-52.
74. Croft, S. L.; Seifert, K.; Yardley, V. Current scenario of drug development for leishmaniasis. Indian J. Med Res., 2006, 123, 399-410.
75. Fournet, A.; Barrios, A. A.; Munoz, V.; Hocquemiller, R.; Cave, A.; Bruneton, J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob. Agents. Chemother., 1993, 37, 859-63.
76. Fournet, A.; Gantier, J. C.; Gautheret, A.; Leysalles, L.; Munos, M. H.; Mayrargue, J.; Moskowitz, H.; Cave, A.; Hocquemiller, R. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J. Antimicrob. Chemother., 1994, 33, 537-44.
77. Fakhfakh, M. A.; Fournet, A.; Prina, E.; Mouscadet, J. F.; Franck, X.; Hocquemiller, R.; Figadere, B. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections. Bioorg. Med. Chem., 2003, 11, 5013-23.
78. Nakayama, H.; Loiseau, P. M.; Bories, C.; Torres de Ortiz, S.; Schinini, A.; Serna, E.; Rojas de Arias, A.; Fakhfakh, M. A.; Franck, X.; Figadere, B.; Hocquemiller, R.; Fournet, A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother., 2005, 49, 4950-6.
79. Desrivot, J.; Edlund, P. O.; Svensson, R.; Baranczewski, P.; Fournet, A.; Figadere, B.; Herrenknecht, C. Metabolism of 2- substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS. Toxicology, 2007, 235, 27-38.
80. Desrivot, J.; Herrenknecht, C.; Ponchel, G.; Garbi, N.; Prina, E.; Fournet, A.; Bories, C.; Figadere, B.; Hocquemiller, R.; Loiseau, P. M. Antileishmanial 2-substituted quinolines: in vitro behaviour towards biological components. Biomed. Pharmacother., 2007, 61, 441-50.
81. Nanayakkara, N. P.; Ager, A. L., Jr.; Bartlett, M. S.; Yardley, V.; Croft, S. L.; Khan, I. A.; McChesney, J. D.; Walker, L. A. Antiparasitic activities and toxicities of individual enantiomers of the 8- aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4- methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob. Agents Chemother., 2008, 52, 2130-7.
82. Jain, M.; Khan, S. I.; Tekwani, B. L.; Jacob, M. R.; Singh, S.; Singh, P. P.; Jain, R. Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues. Bioorg. Med. Chem., 2005, 13, 4458-66.
83. Kaur, K.; Patel, S. R.; Patil, P.; Jain, M.; Khan, S. I.; Jacob, M. R.; Ganesan, S.; Tekwani, B. L.; Jain, R. Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines. Bioorg. Med. Chem., 2007, 15, 915-30.
84. Croft, S. L.; Hogg, J.; Gutteridge, W. E.; Hudson, A. T.; Randall, A. W. The activity of hydroxynaphthoquinones against Leishmania donovani. J Antimicrob Chemother., 1992, 30, 827-32.
85. Mantyla, A.; Garnier, T.; Rautio, J.; Nevalainen, T.; Vepsalainen, J.; Koskinen, A.; Croft, S. L.; Jarvinen, T. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem., 2004, 47, 188-95.
86. Mantyla, A.; Rautio, J.; Nevalainen, T.; Vepsalainen, J.; Juvonen, R.; Kendrick, H.; Garnier, T.; Croft, S. L.; Jarvinen, T. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg. Med. Chem., 2004, 12, 3497-502.
87. Garnier, T.; Mantyla, A.; Jarvinen, T.; Lawrence, M. J.; Brown, M. B.; Croft, S. L. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J. Pharm. Pharmacol., 2007, 59, 41-9.
88. Garnier, T.; Mantyla, A.; Jarvinen, T.; Lawrence, J.; Brown, M.; Croft, S. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother., 2007, 60, 802-10.
89. Manandhar, K. D.; Yadav, T. P.; Prajapati, V. K.; Kumar, S.; Rai, M.; Dube, A.; Srivastava, O. N.; Sundar, S. Antileishmanial activity of nano-amphotericin B deoxycholate. J. Antimicrob. Chemother., 2008, 62, 376-80.
90. Wasan, K. M.; Wasan, E. K.; Gershkovich, P.; Zhu, X.; Tidwell, R. R.; Werbovetz, K. A.; Clement, J. G.; Thornton, S. J. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J. Infect. Dis., 2009, 200, 357-60.
91. Nicoletti, S.; Seifert, K.; Gilbert, I. H. N-(2- hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int. J. Antimicrob. Agents., 2009, 33, 441-8.
92. Nicoletti, S.; Seifert, K.; Gilbert, I. H., Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis. Bioorg. Med. Chem., 2010, 18, 2559-65.
93. Jawahar, M. S. Current trends in chemotherapy of tuberculosis. Indian J. Med. Res., 2004, 120, 398-417.
94. Ellard, G. A. Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Int. J. Lepr. Other Mycobact. Dis., 1984, 52, 395-401.
95. Walker, S. L.; Lockwood, D. N. Leprosy. Clin. Dermatol., 2007, 25, 165-72.
96. Kremsner, P. G.; Krishna, S. Antimalarial combinations. Lancet., 2004, 364, 285-94.
97. Sundar, S.; Rai, M.; Chakravarty, J.; Agarwal, D.; Agrawal, N.; Vaillant, M.; Olliaro, P.; Murray, H. W. New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine. Clin. Infect. Dis., 2008, 47, 1000-6.
98. Melaku, Y.; Collin, S. M.; Keus, K.; Gatluak, F.; Ritmeijer, K.; Davidson, R. N. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg., 2007, 77, 89-94.
99. Wiese, M. Leishmania MAP kinases--familiar proteins in an unusual context. Int. J. Parasitol., 2007, 37, 1053-62.
100. Grant, K. M.; Dunion, M. H.; Yardley, V.; Skaltsounis, A. L.; Marko, D.; Eisenbrand, G.; Croft, S. L.; Meijer, L.; Mottram, J. C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob. Agents Chemother., 2004, 48, 3033-42.
101. Xingi, E.; Smirlis, D.; Myrianthopoulos, V.; Magiatis, P.; Grant, K. M.; Meijer, L.; Mikros, E.; Skaltsounis, A. L.; Soteriadou, K. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int. J. Parasitol., 2009, 39, 1289-303.
102. Naula, C.; Parsons, M.; Mottram, J. C. Protein kinases as drug targets in trypanosomes and Leishmania. Biochim. Biophys. Acta., 2005, 1754, 151-9.
103. Dujardin, J. C.; Gonzalez-Pacanowska, D.; Croft, S. L.; Olesen, O. F.; Spath, G. F. Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas. Trends Parasitol., 2010, 26, 395-403.
104. Ambit, A.; Fasel, N.; Coombs, G. H.; Mottram, J. C. An essential role for the Leishmania major metacaspase in cell cycle progression. Cell Death Differ., 2008, 15, 113-22.
105. Fricker, S. P.; Mosi, R. M.; Cameron, B. R.; Baird, I.; Zhu, Y.; Anastassov, V.; Cox, J.; Doyle, P. S.; Hansell, E.; Lau, G.; Langille, J.; Olsen, M.; Qin, L.; Skerlj, R.; Wong, R. S.; Santucci, Z.; McKerrow, J. H. Metal compounds for the treatment of parasitic diseases. J. Inorg. Biochem., 2008, 102, 1839-45.
106. Bakunov, S. A.; Bakunova, S. M.; Wenzler, T.; Ghebru, M.; Werbovetz, K. A.; Brun, R.; Tidwell, R. R. Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles. J. Med. Chem., 2010, 53, 254-72.
107. Patrick, D. A.; Bakunov, S. A.; Bakunova, S. M.; Kumar, E. V.; Chen, H.; Jones, S. K.; Wenzler, T.; Barzcz, T.; Werbovetz, K. A.; Brun, R.; Tidwell, R. R. Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes. Eur. J. Med. Chem., 2009, 44, 3543-51.
108. Wilson, W. D.; Tanious, F. A.; Mathis, A.; Tevis, D.; Hall, J. E.; Boykin, D. W. Antiparasitic compounds that target DNA. Biochimie., 2008, 90, 999-1014.
109. Lorente, S. O.; Rodrigues, J. C.; Jimenez Jimenez, C.; Joyce- Menekse, M.; Rodrigues, C.; Croft, S. L.; Yardley, V.; de Luca- Fradley, K.; Ruiz-Perez, L. M.; Urbina, J.; de Souza, W.; Gonzalez Pacanowska, D.; Gilbert, I. H. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother., 2004, 48, 2937-50.
110. Lorente, S. O.; Jimenez, C. J.; Gros, L.; Yardley, V.; de Luca- Fradley, K.; Croft, S. L.; J, A. U.; Ruiz-Perez, L. M.; Pacanowska, D. G.; Gilbert, I. H. Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorg. Med. Chem., 2005, 13, 5435-53.
111. Gigante, F.; Kaiser, M.; Brun, R.; Gilbert, I. H. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorg. Med. Chem., 2009, 17, 5950-61.
112. Cammerer, S. B.; Jimenez, C.; Jones, S.; Gros, L.; Lorente, S. O.; Rodrigues, C.; Rodrigues, J. C.; Caldera, A.; Ruiz Perez, L. M.; da Souza, W.; Kaiser, M.; Brun, R.; Urbina, J. A.; Gonzalez Pacanowska, D.; Gilbert, I. H. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother., 2007, 51, 4049-61.
113. Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H.; Fairlamb, A. H. Target assessment for antiparasitic drug discovery. Trends Parasitol., 2007, 23, 589-95.
114. Renslo, A. R.; McKerrow, J. H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol., 2006, 2, 701-10.
115. Hopkins, A. L.; Witty, M. J.; Nwaka, S. Mission possible. Nature, 2007, 449, 166-9.
116. Aguero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F. S.; Campbell, R. K.; Carmona, S.; Carruthers, I. M.; Chan, A. W.; Chen, F.; Crowther, G. J.; Doyle, M. A.; Hertz-Fowler, C.; Hopkins, A. L.; McAllister, G.; Nwaka, S.; Overington, J. P.; Pain, A.; Paolini, G. V.; Pieper, U.; Ralph, S. A.; Riechers, A.; Roos, D. S.; Sali, A.; Shanmugam, D.; Suzuki, T.; Van Voorhis, W. C.; Verlinde, C. L. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 2008, 7, 900-7.
117. Nwaka, S.; Hudson, A., Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov., 2006, 5, 941-55.
118. Nwaka, S.; Ramirez, B.; Brun, R.; Maes, L.; Douglas, F.; Ridley, R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl. Trop. Dis., 2009, 3, e440.
119. Don, R.; Chatelain, E. Drug Discovery for Neglected Diseaes: View of a public private partnership. In: Antiparasitic and antibacterial drug discovery. From molecular targets to drug candidates., 2009, Edited by Paul Selzer, (Wiley-VCH Verlag GmbH & Co KGaA, Weinheim), 33-43.